Menu
Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.
1000 Alfred Nobel Dr
Hercules, California 94547-1811
Phone: 15107247000
www.bio-rad.com
Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market when the pandemic was over. Biotech stocks as a whole have dropped considerably from their pandemic-era highs. Although these stocks have been hit hard lately, some of these investments present long-term opportunities for a savvy investor. Biotechnology is still the wave of the future, with new discoveries helping to treat once-untreatable diseases. New biotech labs still need new equipment to make tomorrow’s new discoveries. As our population ages and diseases become more prevalent, the healthcare industry is set to outpace the economy. The biotech industry will be growing right alongside it. The best-undervalued biotech picks are those that have likely been oversold due to investor skittishness amid rising interest rates. While speculative drug plays aren’t a guarantee of success, many companies are much more well-positioned than people realize.
Tower Research Capital LLC TRC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 88.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 915 shares of the medical research company’s stock after purchasing an additional 430 shares during the quarter. […]
